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Background. To differentiate gastric motility and sensation between type II diabetic patients and controls and explore different
expressions of gastric motility peptides. Methods. Eleven type II diabetic patients and health volunteers of similar age and body
mass index were invited. All underwent transabdominal ultrasound for gastric motility and visual analogue scales. Blood samples
were taken for glucose and plasma peptides (ghrelin, motilin, and glucacon-like peptides-1) by ELISA method. Results. Gastric
emptyingwas significantly slower in diabetic patients than controls (T50: 46.3 (28.0–52.3)min versus 20.8 (9.6–22.8)min,𝑃 ≤ 0.05)
and less antral contractions in type II diabetic patients were observed (𝑃 = 0.02). Fundus dimensions did not differ. There were a
trend for less changes in gastrointestinal sensations in type II diabetic patients especially abdomen fullness, hunger, and abdominal
discomfort. Although the serum peptides between the two groups were similar a trend for less serum GLP-1in type II diabetic
patients was observed (𝑃 = 0.098). Conclusion. Type II diabetic patients have delayed gastric emptying and less antral contractions
than controls. The observation that there were lower serum GLP-1 in type II diabetic patients could offer a clue to suggest that
delayed gastric emptying in diabetic patients is not mainly influenced by GLP-1.
1. Introduction
Gastrointestinal tract disorders are common in diabetic
patients [1, 2]. More than 75% of patients visiting diabetes
mellitus clinics reported significant gastrointestinal symp-
toms [1] such as dysphasia, early satiety, reflux, abdominal
pain, nausea, vomiting, constipation, and diarrhea. The
symptoms may be severe enough to substantially affect qual-
ity of life, induce poor sugar control, and progress with dura-
tion of diabetes mellitus. The pathogenesis of the gastroin-
testinal abnormalities is multifactorial complex in nature
which may involve autonomic neuropathy, motor dysfunc-
tion, glycemic control, psychological factors, and so forth
and is not well understood [3]. In diabetic patients with
gastrointestinal symptoms, 68% were found to have delayed
gastric emptying [4] that influences the quality of life and
sugar control in these patients. Owing to the fact that the
pathogenesis is still poorly understood, it is rational that the
effective medical treatment for these patients with diabetic
dyspepsia is yet unavailable. Gastric motility is regulated by
gastrointestinal motility hormones such as cholecystokinin,
gastric inhibitor peptide, motilin, and ghrelin. Previous
publications reported that motilin [5, 6] and ghrelin [7, 8]
stimulated gastricmotility and glucagon-like peptide-1 (GLP-
1) inhibited gastric motility [9, 10]. We hypothesized that
diabetic patients had lower motilin and ghrelin or higher
GLP-1 and hence inhibited gastric motility and induced gas-
trointestinal symptoms. Therefore, we conducted this study
to compare gastric motility and sensation between type II
diabetic patients and normal controls and explore the roles
of different gastric motility peptides in this motility effect.
2. Methods
Eleven patients (2 female) with long-standing (>5 years) type
II diabetes mellitus (DM) and 11 healthy controls (2 female)
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Table 1: The basic characteristics between type II DM and normal control.
Type II DM (11) Normal controls (11) P
Age (years) 58 ± 2 51 ± 5 NS
Gender (female/male) 2/11 2/11 NS
BMI (kg/m2) 23.7 ± 2.5 25.0 ± 2.2 NS
Duration of DM (years) 11.1 ± 5.6 0 0.000∗
Fasting glucose 126.0 ± 32.1 82.0 ± 4.9 0.012∗
HbA1C 9.5 ± 1.3 5.5 ± 0.1 0.000∗
∗Significant statistic difference.
of similar age (58±2 years; 51±5 years) andbody mass index
(25.0 ± 2.2 kg/m2; 23.7 ± 2.5) were invited to participatein
current study from August 2009 to July 2010. The basic
demographic data were listed in Table 1. All patients gave
written, informed consent, and the protocol was approved
by both the institutional Review Board and the Research
Ethics Committee of Kaohsiung ChangGungMemorial Hos-
pital, Taiwan (IRB 96-1583B). Patients were excluded if they
had a historyof ketosis or dysautonomic or gastrointestinal
symptoms determined by interview or from the review of
medical records. All patients with type II diabetes mellitus
in current study were prescribed with oral hypoglycemic
agents instead of insulin therapy. Subjects were also excluded
if they had previous gastrointestinal disease or abdominal
surgery with the exception of uncomplicated appendectomy,
herniorrhaphy, or gynecologicsurgery. All patients must
discontinue medications including anticholinergics, calcium
channel blockers, 3-adrenergicantagonists, or hormones 48
hours before the study except oral hypoglycemic agents.
They underwent physical examination, laboratory blood tests
(including white-cell and red-cell counts, measurement of
blood sugar during fasting, and liver-function tests), abdomi-
nal ultrasonography, and upper gastrointestinal endoscopy to
rule out any structural cause for the symptoms.
Each subject was studied on afternoons. Following a fast
of 8 h for solids and liquids, the patients consumed 500mL of
chicken and corn soup (UnitedKanboo, Taipei, Taiwan), con-
taining 118.6 kcal (2.6 g protein, 2.6 g fat, 21.2 g carbohydrate).
The soupwas boiled and subsequently cooled to 37∘Candwas
consumed over 5min (𝑡 = −5–0min). All patients underwent
transabdominal ultrasound to record antral area, fundic area,
and diameterandantral contractions in regular time by using
an Aloka SSD-2000 CL Ultrasound Machine (Aloka, Tokyo,
Japan) with a 3.5-MHz annular array probe.The frequency of
antral contractionswas defined as the number of contractions
during a 25-minute interval, recorded per five minutes, and
the antral contractions were defined as one time while the
maximal contraction-induced reduction of the antral area
(difference between relaxed and contracted area) as a fraction
of the relaxed area (Δ𝐴/𝐴) > 50% as our previous study [11].
All subjects were invited to denote their symptoms 10min
before testmeal ingestion and 10min after testmeal ingestion.
A questionnaire with visual analogue scales (VAS) for the
symptoms of pain, nausea, abdominal discomfort, bloating,
and abdominal fullness was administered every ten minutes
till 90min. Grading was made on a 100mm unmarked
line between “no symptom” at one end and “excruciating
symptoms” at the other. Blood sampleswere taken at𝑇 = −10,
30, 60, and 90 minutes for measurement of blood glucose
and plasma peptide levels. Blood glucose concentrations
were immediately determined using a portable blood glucose
meter (MediSense Companion 2 meter; MediSense Inc.,
Waltham, MA, USA). The accuracy of this method has been
confirmed using the hexokinase technique. Venous blood
samples were collected into ice-chilled EDTA-treated tubes
containing 400KIU aprotinin/mL blood. Plasma was sepa-
rated and samples stored at −70∘C for subsequent analysis of
GLP-1, ghrelin and motilin concentrations. Plasma ghrelin,
motilin, and GLP-1 concentrations were measured by ELISA
(Ghrelin was measured by a commercial ELISA kit (Phoenix
Pharmaceuticals Inc., Burlingame, CA); intra- and interassay
coefficients of variation (CV) were less than 5% and less than
9%, respectively; motilin and GLP-1 were also measured by a
commercial ELISA kit.
3. Statistical Analysis
The curves for antral area, fundic area, diameter, antral
contractions, and gastrointestinal sensation scores were com-
pared by using repeated measures ANOVA. Linear regres-
sion analysis was used to examine relationships between
gastrointestinal sensations and gastric motility (antral area,
fundic area, diameter, and frequency of antral contraction).
Results were shown as means ± standard deviation. 𝑃 values
<0.05 were considered significant. Mean values and standard
deviations (SD) of each variable were calculated if not specifi-
cally noted otherwise. Statistical analysis was performed with
Student’s 𝑡-test for paired comparison. The tests are two-
tailed, and 𝑃 < 0.05 is considered significant.
4. Results
All subjects tolerated the study well.
4.1. Antral Area and Gastric Emptying. Antral area was larger
in type II diabetic patients than normal controls especially
after test meal (antal area 15.6 ± 2.3 cm2 versus 12.6 ±
2.4 cm2). Gastric emptying was more significant in normal
controls than diabetic patients (T50: 20.8 (9.6–22.8) min
versus 46.3 (28.0–52.3) min, 𝑃 = 0.03). There was a statistical
significance trend for smaller antral area in the normal
controls between the two groups, 𝑃 = 0.014 (Figure 1(a)).
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Figure 1: (a) There was a statistical significance trend for smaller antral area in the normal controls between the two groups; 𝑃 = 0.014.
(b) There was a significant trend for less antral contractions in type II diabetic patients during 90 minutes after the test meal (𝑃 = 0.02). (c)
Fundus dimensions did not differ between normal controls and type II diabetic patients (fundic area: 𝑃 = 0.454; fundic diameter: 𝑃 = 0.331).
4.2. Antral Contractions. There was a significant trend for
less antral contractions in type II diabetic patients during 90
minutes after the test meal (𝑃 = 0.02) (Figure 1(b)).
4.3. Fundic Area and Diameter. Fundus dimensions did not
differ between normal controls and type II diabetic patients
(fundic area: 𝑃 = 0.454; fundic diameter: 𝑃 = 0.331) (Figures
1(c) and 1(d)).
4.4. Gastrointestinal Sensations. Soup ingestion was associ-
ated with increased abdominal fullness and bloating and
decreased hunger and appetite scores only in control group
but not in type II diabetic patients. Figure 2 demonstrated
a trend for less significant changes in gastrointestinal sensa-
tions in type II diabetic patients especially abdomen fullness,
hunger, and appetite in current study.
4.5. Gastric Motility Peptides. There were no differences in
serum peptide (motilin, ghrelin, and GLP-1) between the two
groups but a trend for less serum GLP-1 in patients with type
II diabetes mellitus was observed (𝑃 = 0.098) (Figure 3).
5. Discussion
Faraj and colleagues reported as high as 68% of the diabetic
patients with gastrointestinal symptoms were associated with
delayed gastric emptying [4]. In current study, we observed
that type II diabetic patients were found to have larger gastric
antral area on sonography. Type II diabetic patients had
delayed gastric emptying and less gastric contraction and
experienced less postprandial sensation than normal volun-
teers probably owing to gastric atony and gastric paralysis
(gastroparesis) in diabetic patients.
As we had shown that less gastric contraction in diabetic
patients were correlated with less gastric emptying, there
were reports indicating that diabetic patients had postpran-
dial antral hypomotility, decreased temporal organization of
antral pressure waves, and increased small intestinal motor
activity. All these gastric disorders occurred in long-term
diabetic patients and were associated with peripheral neu-
ropathy. Prolonged poor sugar control induced sympathetic
nerve dysfunction. Samsom and colleagues observed a lower
fasting fundal tone and a decrease in volume change of
the gastric fundus after a nutrient drink in patients with
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Figure 2: A trend for less significant changes in gastrointestinal sensation in type II diabetic patients especially abdomen fullness, hunger, and
appetite in current study (abdomen fullness (𝑃 = 0.14), hunger (𝑃 = 0.139), appetite (𝑃 = 0.112), nausea (𝑃 = 0.904), discomfort (𝑃 = 0.7),
and motility (𝑃 = 0.485)).
autonomic neuropathy due to type I diabetes mellitus but
the fundus dimensions between type II diabetic patients with
normal controls were not different in current study. They
used barostat to measure fundic volume and tone but we
used ultrasound to detect fundic dimensions. Kumar and
colleagues then emphasized more significant impairment in
gastric fundic volume and the accommodation response to
a test meal in diabetic patients [12] but we still did not
observe the difference in our study.The plausible explanation
could be the low nutrient test meal we used in current study.
Low volume test meal would not remain in the fundus long
enough to be detected by abdominal ultrasound. Perhaps
such drawback could be overcome if higher nutrient test
meals were used. Other than this, computer tomography
might be a better imaging study to overcome the difference.
Type II diabetic patients experienced less gastrointestinal
sensation after a test meal than normal controls in spite of
significant delaying gastric emptying and decreasing gastric
contraction. Loo and colleagues found out that approximately
50% of these patients with gastric motor disorders might be
asymptomatic [13].
It is still unclear about the actual roles of differentmotility
expression in diabetic patients. Motilin had been reported
to regulate the interdigestive migrating contractions (IMC),
the fasted motor pattern in the gastrointestinal tract [14], and
ghrelin stimulated GI motility. Ghrelin induced premature
phase III contractions of IMC in the human stomach [7] and
intravenous ghrelin injection could accelerate gastric emp-
tying and improve meal-related symptoms. All these reports
suggested that ghrelin could be a potential prokinetic agent.
More studies are mandatory to clarify the physiological role
of plasma ghrelin andmotilin in these digestive physiological
events and stimulation of gastric emptying. However, we
observed no different motilin and ghrelin between diabetic
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Figure 3: There were no differences in serum peptides (motilin,
ghrelin, and GLP-1) between two groups but a trend for less serum
GLP-1 in patients with type II diabetes mellitus was observed (𝑃 =
0.098).
patients and normal controls, only a trend of less serumGLP-
1 expression in type II diabetic patients in current study. This
could not well explain the pathology of delayed gastric emp-
tying in our diabetic patients. This was consistent with the
findings of Pala and colleagueswho reported thatGLP-1 levels
were significantly lower in subjects with impaired glucose
tolerance and type 2 diabetes mellitus compared to those
with normal glucose tolerance [15]. Shirra and Delgado-Aros
and colleagues observed that GLP-1 significantly inhibited
gastric emptying and vagal function [16, 17]. Rosenstock and
colleagues even used GLP-1 agonists to treat diabetic patients
[18, 19]. There was limitation in our study, small patient
number that could cause why there was no difference in
motility peptides in current study.
In conclusion, Type II diabetic patients have delayed
gastric emptying and less antral contractions than normal
controls andmay be associated to less postprandial sensation.
The observation that less serum GLP-1 in type II diabetic
patients could offer a clue to understand that delayed gastric
emptying in diabetic patients is not mainly regulated by
GLP-1.
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